<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202630</url>
  </required_header>
  <id_info>
    <org_study_id>09-SUS-05-BIK-02</org_study_id>
    <nct_id>NCT01202630</nct_id>
  </id_info>
  <brief_title>BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection</brief_title>
  <official_title>A Triple-blind, Randomized, Placebo-controlled, Multi-center Study on the Effect of BIO-K+ CL1285 for Prevention of Recurrent Clostridium Difficile Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio-K Plus International Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sprim Advanced Life Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Bio-K Plus International Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of BIO-K+ CL1285 for&#xD;
      prevention of recurrent Clostridium difficile infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    The site is unable to recruit patients.&#xD;
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of recurrent Clostridium difficile infection</measure>
    <time_frame>60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of recurrent diarrhea episodes</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of gastrointestinal symptoms</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Recurrent Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BIO-K+ CL1285</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus acidophilus CL1285® and Lactobacillus casei</intervention_name>
    <description>2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>BIO-K+ CL 1285</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 capsules of placebo (no live cells), consumed once daily for 60 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Presence of two or more loose or liquid stools in the 24-hour period prior to&#xD;
             initiation of antibiotic therapy&#xD;
&#xD;
          3. Hospitalized and starting antibiotic therapy for Clostridium difficile infection (CDI)&#xD;
             or recurrent Clostridium difficile infection (RCDI), diagnosed with a positive stool&#xD;
             culture&#xD;
&#xD;
          4. Agree to use contraception throughout study period, unless postmenopausal or&#xD;
             surgically sterile (females only)&#xD;
&#xD;
          5. Understand the nature and purpose of the study including potential risks and side&#xD;
             effects&#xD;
&#xD;
          6. Willing to comply with the requirements of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of 2 or more clostridium difficile infections at any time prior to the current&#xD;
             episode&#xD;
&#xD;
          2. Presence of severe chronic and/or inflammatory condition&#xD;
&#xD;
          3. Impaired immunity, e.g. undergoing immunotherapy or chemotherapy&#xD;
&#xD;
          4. Major gastrointestinal complication, e.g. Crohn's disease or ulcer&#xD;
&#xD;
          5. Current treatment with nasogastric tube, ostomy, or parenteral nutrition&#xD;
&#xD;
          6. Use of proton pump inhibitors&#xD;
&#xD;
          7. Pregnant female or breastfeeding&#xD;
&#xD;
          8. Eating disorder&#xD;
&#xD;
          9. History of alcohol, drug, or medication abuse&#xD;
&#xD;
         10. Daily consumption of probiotics, fermented milk, and/or yogurt&#xD;
&#xD;
         11. Known allergies to any substance in the study product&#xD;
&#xD;
         12. Participation in another study with any investigational product within 3 months of&#xD;
             screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cornelius J Foley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Parker Jewish for Health Care and Rehabilitation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parker Jewish Institute</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gao XW, Mubasher M, Fang CY, Reifer C, Miller LE. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010 Jul;105(7):1636-41. doi: 10.1038/ajg.2010.11. Epub 2010 Feb 9.</citation>
    <PMID>20145608</PMID>
  </reference>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2010</study_first_posted>
  <last_update_submitted>January 14, 2016</last_update_submitted>
  <last_update_submitted_qc>January 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clostridium difficile</keyword>
  <keyword>diarrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Enterocolitis, Pseudomembranous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

